Abstract
Oral cancer is the sixth most frequent cancer worldwide. Prognosis for these patients remains poor. Recently, the epidermal growth factor receptor has been targeted as an adjunct to radiotherapy and surgery with limited success. The authors now present data suggesting that the alphanubeta6 integrin, which is a marker for aggressive oral cancer, may regulate epidermal growth factor receptor expression. The authors suggest perhaps targeting both alphanubeta6 and EGFR may provide additional benefits.
MeSH terms
-
Antibodies, Monoclonal
-
Antigens, Neoplasm / analysis
-
Antigens, Neoplasm / physiology*
-
Biomarkers, Tumor / analysis
-
Blotting, Western
-
Carcinoma, Squamous Cell / pathology*
-
Cell Line, Tumor
-
Cell Membrane / pathology
-
ErbB Receptors / analysis
-
ErbB Receptors / physiology*
-
Extracellular Matrix / pathology
-
Fluorescein-5-isothiocyanate
-
Fluorescent Dyes
-
Humans
-
Immunohistochemistry
-
Integrins / analysis
-
Integrins / physiology*
-
Mouth Neoplasms / pathology*
-
Neoplasm Invasiveness
-
Proto-Oncogene Proteins c-fyn / physiology
-
Signal Transduction / physiology
Substances
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
Biomarkers, Tumor
-
Fluorescent Dyes
-
Integrins
-
integrin alphavbeta6
-
ErbB Receptors
-
Proto-Oncogene Proteins c-fyn
-
Fluorescein-5-isothiocyanate